Barclays has initiated coverage on Exelixis Inc (EXEL) with an Equal-Weight rating, marking its first assessment of the biotechnology firm's investment potential. This decision reflects Barclays' analysis of Exelixis' business dynamics and growth prospects in the oncology sector.
Headquartered in Alameda, California, Exelixis focuses on developing and commercializing new medicines for challenging cancers. The company has four marketed pharmaceutical products, including cabozantinib, which is approved for multiple cancer indications. Exelixis is also advancing its product pipeline, notably with its lead investigational asset, zanzalintinib.
As of September 16, 2025, Exelixis shares are priced at $42.20. The company boasts a market capitalization of $11.3 billion, a P/E ratio of 16.67, and an EPS of 2.38. Upcoming earnings are anticipated on May 11, 2026, with an estimated EPS of $0.78 and revenue of $641.0 million.
Analyst consensus currently indicates a Buy rating, with 7 Strong Buy, 10 Buy, and 9 Hold ratings among 26 total assessments. Recent analyst actions include Goldman Sachs initiating a Buy rating and Morgan Stanley maintaining an Overweight rating, both on September 17, 2025. Such decisions reflect a broader confidence in Exelixis’ growth trajectory as it continues to innovate in the oncology space.